Pfizer Appoints Head of Vaccines - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Pfizer Appoints Head of Vaccines



Pfizer has named Albert Bourla as group president of the company’s Vaccines, Oncology and Consumer Healthcare business and Susan Silbermann as president and general manager, Global Vaccines business, both effective Jan. 1, 2014.
 
Doug Lankler, who was to become general counsel on January 1, and Rady Johnson who was to become chief compliance and risk officer on January 1, both assume their new positions immediately. 

On January 1, the company will begin operating with three commercial businesses-the Global Innovative Pharmaceutical business, led by Geno Germano, the Global Established Pharmaceutical business, led by John Young, and the Vaccines, Oncology, and Consumer Healthcare business led by Albert Bourla.

Source: Pfizer

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
27%
Breakthrough designations
9%
Protecting the supply chain
41%
Expedited reviews of drug submissions
9%
More stakeholder involvement
14%
View Results
Jim Miller Outsourcing Outlook Jim Miller Health Systems Raise the Bar on Reimbursing New Drugs
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerThe Mainstreaming of Continuous Flow API Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler Industry Seeks Clearer Standards for Track and Trace
Siegfried Schmitt Ask the Expert Siegfried SchmittData Integrity
Sandoz Wins Biosimilar Filing Race
NIH Translational Research Partnership Yields Promising Therapy
Clusters set to benefit from improved funding climate but IP rights are even more critical
Supplier Audit Program Marks Progress
FDA, Drug Companies Struggle with Compassionate Use Requests

Click here